Abstract
Breast carcinoma is one of the leading causes of mortality among female cancers globally. Heparan sulfate proteoglycans, found predominantly on cell surfaces and in the extracellular matrix, are known to regulate breast cancer cellular behavior. Many studies have shown that these molecules serve as potential biomarkers for breast cancer. In addition, they have aberrant expression patterns and participate in various molecular signaling pathways in tumor progression. There is substantial interest in targeting heparan sulfate proteoglycans for cancer treatment, which needs to be tailored according to the roles that each proteoglycan plays in cancer biology. Current clinical trials using phosphomannopentaose sulfate, a heparan sulfate mimic, and various forms of heparin have produced promising results in breast cancer patients. Besides heparan sulfate chains, novel therapeutic agents could potentially be developed to regulate the proteoglycan core proteins as well as enzymes that modify heparan sulfation patterns. This review discusses the current use and future prospective applications of heparan sulfate proteoglycans, which have been recently patented, as therapeutic targets in breast cancer treatment.
Keywords: Breast cancer, heparan sulfate, heparin, syndecan, glypican, glycosaminoglycans, proteoglycans, phosphomannopentaose sulfate, endosulfatase, heparanase
Recent Patents on Anti-Cancer Drug Discovery
Title: Targeting Heparan Sulfate Proteoglycans in Breast Cancer Treatment
Volume: 3 Issue: 3
Author(s): Chuay-Yeng Koo, Yin-Ping Sen, Boon-Huat Bay and George W. Yip
Affiliation:
Keywords: Breast cancer, heparan sulfate, heparin, syndecan, glypican, glycosaminoglycans, proteoglycans, phosphomannopentaose sulfate, endosulfatase, heparanase
Abstract: Breast carcinoma is one of the leading causes of mortality among female cancers globally. Heparan sulfate proteoglycans, found predominantly on cell surfaces and in the extracellular matrix, are known to regulate breast cancer cellular behavior. Many studies have shown that these molecules serve as potential biomarkers for breast cancer. In addition, they have aberrant expression patterns and participate in various molecular signaling pathways in tumor progression. There is substantial interest in targeting heparan sulfate proteoglycans for cancer treatment, which needs to be tailored according to the roles that each proteoglycan plays in cancer biology. Current clinical trials using phosphomannopentaose sulfate, a heparan sulfate mimic, and various forms of heparin have produced promising results in breast cancer patients. Besides heparan sulfate chains, novel therapeutic agents could potentially be developed to regulate the proteoglycan core proteins as well as enzymes that modify heparan sulfation patterns. This review discusses the current use and future prospective applications of heparan sulfate proteoglycans, which have been recently patented, as therapeutic targets in breast cancer treatment.
Export Options
About this article
Cite this article as:
Koo Chuay-Yeng, Sen Yin-Ping, Bay Boon-Huat and Yip W. George, Targeting Heparan Sulfate Proteoglycans in Breast Cancer Treatment, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (3) . https://dx.doi.org/10.2174/157489208786242278
DOI https://dx.doi.org/10.2174/157489208786242278 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
microRNAs Downregulation in Cancer is Associated with Guanine Enrichment in the Terminal Loop Sequences of their Precursors
MicroRNA Anti-Angiogenic Therapies for Children with Cancer
Current Cancer Drug Targets Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?
Current Drug Targets Drug Combinations Enhancing the Antineoplastic Effects of Erlotinib in High-Grade Glioma
Recent Patents on Anti-Cancer Drug Discovery Mobile Phone Based Biomedical Imaging Technology: A Newly Emerging Area
Recent Patents on Biomedical Engineering (Discontinued) Synthesis and Stability Evaluation of New HYNIC Derivatives as Ligands for Technetium-99m
Letters in Organic Chemistry The Tumor Stroma as Mediator of Drug Resistance - A Potential Target to Improve Cancer Therapy?
Current Pharmaceutical Biotechnology Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism
Current Drug Metabolism Sex Hormones and their Analogues in Neuroimmune Biology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Origin of Lentivirus Research: Maedi-Visna Virus
Current HIV Research Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Inflammatory Caspases: Targets for Novel Therapies
Current Pharmaceutical Design Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Nanomedicine: A New Frontier in Cancer Therapeutics
Current Drug Delivery The Role of Survivin for Radiation Oncology: Moving Beyond Apoptosis Inhibition
Current Medicinal Chemistry Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
Current Cancer Drug Targets Efficacy and Safety of Nonopioid Analgesics in Perioperative Pain Control
Current Drug Safety Meta-analysis Reveals No Association of DNMT3B -149 C>T Gene Polymorphism With Overall Cancer Risk
Current Genomics A Perspective on 10-Years HTS Experience at the Walter and Eliza Hall Institute of Medical Research – Eighteen Million Assays and Counting
Combinatorial Chemistry & High Throughput Screening